Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


April 28, 2023

The American Diabetes Association recommends SGLT2 inhibitors in patients with type 2 diabetes and established ASCVD, regardless of the patient's hemoglobin A1c. SGLT2 inhibitors have been shown to significantly reduce the risk for major adverse cardiovascular events, cardiovascular mortality, heart failure, and chronic kidney disease. In the EMPA-REG OUTCOME trial, empagliflozin was shown to reduce the risk for cardiovascular death by 38% and decline in glomerular filtration rate. This was later shown to be a class effect through the 2017 CANVAS trial; individuals who received canagliflozin experienced a 30% reduction in the risk for heart failure hospitalizations, cardiovascular death, and end-stage kidney disease.

DPP-4 inhibitors may be used in patients with renal impairment. However, uncertainties have been raised regarding heart failure risks.

Learn more about type 2 diabetes treatments.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.